Compare Lennar Corporation (LEN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Viatris Inc — how do they compare? Lennar Corporation trades at $82.12 (market cap $19.92B), while Viatris Inc trades at $17.37 (market cap $19.79B). The key difference: Lennar Corporation and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| LEN | VTRS | |
|---|---|---|
Market Cap | $19.92B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $17.39 |
52-Week Low | $82.30 | $8.74 |
Enterprise Value | $23.80B | $32.00B |
Dividend Yield | 2.41% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $82.53, down 1.62% today, with a bearish technical signal and recent earnings misses. The stock shows attractive valuation metrics with a P/E of 13.15 and P/S of 0.64, but faces margin compression as net income fell to $2.08 billion in 2025. Recent news highlights housing affordability challenges and the company's strategy to prioritize volume over price, with average selling prices at 2017 levels (The Motley Fool, June 24, 2026).
The outlook is mixed: analyst consensus is a Buy with a $84.78 target, but technicals and earnings trends suggest near-term pressure. Key risks include rising mortgage rates and housing demand softness, while potential catalysts include margin recovery efforts and supportive housing legislation. Execution on cost discipline and market share gains will be critical for upside.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
